The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 14, Issue 8, 1999, Pages 1912-1916

  Ertürk, Şehsuvar ^a,b   Nergizoǧlu, Gökhan ^a   Ateş, Kenan ^a   Duman, Neval ^a   Erbay, Bülent ^a   Karatan, Oktay ^a   Ertuǧ, A Ergün ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

ACE inhibitors; Anaemia; Erythropoietin; Haemodialysis; Hypertension; Left ventricular hypertrophy

Indexed keywords

ALDOSTERONE; ALUMINUM; AMLODIPINE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; ERYTHROPOIETIN; FELODIPINE; PARATHYROID HORMONE; PERINDOPRIL; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL ARTICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; KIDNEY FAILURE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 18744431818     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.8.1912     Document Type: Article

References (38)

1. Escbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis 1988; 11: 203-209
2. Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anemia of chronic renal failure with recombinant human erythropoietin: a European multicenter study in 142 patients to define dose regimen and safety profile. Nephrol Dial Transplant 1991; 6: 955-965
3. Escbach JW, DeOreo P, Adamson J et al. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30 [Suppl 3]: S192-S240
4. Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13 [Suppl 2]: 23-27
5. Silberberg JS, Rahal DP, Patton DR, Sniderman AD. Role of anemia in the pathogenesis of left ventricular hypertrophy in end-stage renal disease. Am J Cardiol 1989; 64: 222-224
6. Greaves SC, Gamble GD, Collins JF, Whalley GA, Sharpe N. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis 1994; 24: 768-776
7. Ertürk Ş, Ertuǧ AE, Ateş K et al. Relationship of ambulatory blood pressure monitoring data to echocardiographic findings in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 2050-2054
8. Diez J, Laviades C. Insulin-like growth factor-I and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril, and quinalapril. J Hypertens 1994; 12 [Suppl]: S31-S36
9. Sasaki M, Oki T, Iuchi A et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies. J Hypertens 1996; 12: 1403-1408
10. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997; 12: 945-951
11. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolong therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-664
12. Sennesael J, Verbeelen D. Therapeutic efficacy and tolerance of two orally active angiotensin converting enzyme inhibitors in patients undergoing regular hemodialysis. Kidney Int 1985; 28: A252 [Abstract]
13. Gould AB, Goodman SA. Effect of angiotensin-converting enzyme inhibitor on blood pressure and erythropoiesis in rats. Eur J Pharmacol 1990; 181: 225-234
14. Hirakata H, Onoyama K, Hori K, Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 1986; 26: 27-32
15. Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1358
16. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 1996; 28: 535-540
17. Schwenk MH, Jumani AQ, Rosenberg CR, Kulogowski JE, Charytan C, Spinowitz BS. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis. Pharmacotherapy 1998; 18: 627-630
18. Ertürk Ş, Ateş K, Duman N, Karatan O, Erbay B, Ertuǧ E. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients. Possible implications of angiotensin converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-397
19. Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210
20. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
21. Sahn DJ, De Maria A, Kisslo J, Weyman A. Committee on M-mode standardization of the American Society of Echocardiography. Recommendations regarding quantification in M-Mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083
22. Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458
23. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
24. Bauer JH, Reams GP. Antihypertensive drugs. In: Brenner BM (ed). The Kidney. WB Saunders, Philadelphia; 1996: 2331-2381
25. Motz W, Klepzig M, Strauer BE. Regression of cardiac hypertrophy: experimental and clinical results. J Cardiovasc Pharmacol 1987; 10 [Suppl 6]: S148-S152
26. Nakao K, Shirakura T, Azuma M, Maekawa T. Studies on erythropoietic action of angiotensin II. Blood 1967; 29: 754-760
27. Gould AB, Goodman SA, DeWolf R, Onesti G, Swartz C. Interrelation of the renin system and erythropoietin in rats. J Lab Clin Med 1980; 96: 523-534
28. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest 1997; 100: 2310-2314
29. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol 1998; 354: 179-187
30. Gossmann J, Thürmann P, Bachmann T et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 1996; 50: 973-978
31. Julian BA, Brantley RR Jr, Barker CV et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998; 9: 1104-1108
32. Morrone LF, Di Paolo S, Logoluso F et al. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients. Transplantation 1997; 64: 913-918
33. Akpolat T, Gümüş T, Bedir A, Adam B. Acute effect of trandolapril on serum erythropoietin in uremic and hypertensive patients. J Nephrol 1998; 11: 94-97
34. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62: 25-31
35. Kamper A-L, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990; 50: 611-618
36. Navarro JF, Mora C, Rivero A. Effect of angiotensin-converting enzyme inhibitors on hematological parameters and recombinant human erythropoietin doses in peritoneal dialysis patients. Nephron 1998; 80: 239
37. Macdougall IC, Allen DA, Cavill I, Baker LRI, Raine AEG. Interleukin-3 potentiates the effect of erythropoietin in a uraemic anaemic animal model. Nephrol Dial Transplant 1994; 9: 1032-1033
38. Goicoechea M, Martin J, De Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343